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The somatostatin analog octreotide (OCT) displays important neuroprotective and anti-
angiogenic properties that could make it an interesting candidate to treat diabetic
retinopathy (DR). Unfortunately, systemic drug administration is hindered by severe side
effects, therefore topical administration routes are preferable. However, drug delivery
through eye drops may be difficult due to ocular barriers and, in the long term, could
induce ocular damage. On the other hand, intraocular injections must be repeated
to maintain drug concentration, and this may cause severe damage to the eye. To
decrease injection frequency, long-term release and reduced biodegradation could be
obtained by binding the drug to biodegradable polymeric nanoparticles. In the present
study, we made a preparation of OCT bound to magnetic nanoparticles (MNP-OCT) and
tested its possible use as an OCT delivery system to treat retinal pathologies such as
DR. In particular, in vitro, ex vivo, and in vivo experimental models of the mammalian
retina were used to investigate the possible toxicity of MNPs, possible effects of the
binding to MNPs on OCT bioactivity, and the localization of MNP-OCT in the retina after
intraocular injection. The results showed that, both in human retinal endothelial cells
(HRECs) and in mouse retinal explants, MNPs were not toxic and the binding with MNPs
did not influence OCT antiangiogenic or antiapoptotic activity. Rather, effects of MNP-
OCT were observed at concentrations up to 100-fold (in HRECs) or 10-fold (in mouse
retinal explants) lower compared to OCT, indicating that OCT bioactivity was enhanced
in MNP-OCT. MNP-OCT in mouse retinas in vivo after intraocular delivery were initially
localized mainly to the outer retina, at the level of the retinal pigment epithelium, while
after 5 days they were observed throughout the retinal thickness. These observations
demonstrate that MNP-OCT may be used as an OCT intraocular delivery system that
may ensure OCT localization to the retina and enhanced OCT bioactivity. Further studies
will be necessary to determine the OCT release rate in the retina and the persistence of
drug effects in the long period.
Keywords: mammalian retina, pigment epithelium, endothelial cells, retinal explants, apoptosis, biocompatibility,
bioactivity
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INTRODUCTION
Diabetic retinopathy (DR) is a complication of diabetes that
represents one of the major causes of vision loss in humans.
The endogenous neuropeptide somatostatin has been widely
studied for its powerful neuroprotective properties that may
be exploited for DR treatment, and these studies have been
extensively reviewed (Gabriel, 2013; Hernandez et al., 2014;
Szabadfi et al., 2014; Simo-Servat et al., 2018; Cervia et al.,
2019). In particular, the treatment with the somatostatin analog
octreotide (OCT) has been found to inhibit apoptotic cell
death and avoid vascular endothelial growth factor (VEGF)
overexpression in retinal explants exposed to typical diabetic
stressors such as hyperglycemia, oxidative stress (OS) or
advanced glycation end-products (Amato et al., 2016). OCT
has been shown also to maintain the apoptosis-autophagy
equilibrium in high glucose conditions by promoting the
restoration of the autophagic flux in bipolar, amacrine, and
ganglion cells (Amato et al., 2018a). OCT may also exert
antiangiogenic effects, which may be of importance for the
treatment of belated stages of DR characterized by aberrant
angiogenesis. Indeed, OCT strongly inhibited VEGF-induced
cell proliferation, migration and tubulogenesis in human retinal
endothelial cells (HRECs) (Palii et al., 2008), prevented hypoxia-
induced VEGF upregulation in retinal explants (Mei et al., 2012),
and reduced VEGF expression and angiogenesis in a mouse
model of oxygen-induced retinopathy (Dal Monte et al., 2009).
Somatostatin or OCT seem to open interesting possibilities for
new DR treatments. However, although systemic administration
of these factors could be a simple and non-invasive treatment
modality, it is affected by important limitations due to the
possible occurrence of adverse side effects. For instance, long-
term systemic administration of somatostatin or OCT could
provoke gastritis, damage of the gastric mucosa, and focal
atrophy (Plockinger et al., 1990). In order to avoid systemic
side effects, topical administration routes are generally preferred.
For instance, drug delivery through eye drops is a non-
invasive and non-stressing modality. However, achievement and
maintenance of the effective drug concentration in the retinal
microenvironment are hindered by external ocular barriers
represented by cornea/sclera and the tear film (Agarwal et al.,
2016). Moreover, the long-term treatment with eye drops
could lead to corneal dryness, inflammation, and damage
(Baudouin et al., 2010).
Commonly, diseases of the posterior segment of the eye are
treated with drugs administered intravitreally, which ensures
the achievement of effective intraocular drug concentrations.
However, the long-term maintenance of the effective drug
levels requires relatively frequent intravitreal injections, which
represent the main limitation of this modality of ocular
drug delivery. Indeed, many severe adverse effects may occur
after a long period of high frequency intraocular injections,
such as retinal detachment, endophthalmitis, cataract, ocular
hypertension, and submacular hemorrhages (Krishnan et al.,
2009; Adelman et al., 2010).
Biocompatible nanoparticle technology has emerged as
a promising drug delivery system allowing specific drug
binding/entrapment, enhancing long-term drug release, and
reducing time-dependent drug biodegradation (Singh and
Lillard, 2009; Lee and Yeo, 2015; Patra et al., 2018). Generally,
nanoparticles are designed to be biocompatible, non-antigenic
and highly hydrophilic in nature (Li et al., 2012; Naahidi et al.,
2013). Different types of nanoparticles have been tested as
carriers for the intraocular delivery of drugs inhibiting choroidal
or intraretinal neovascularization, thus indicating therapeutic
potential for age-related macular degeneration (Park et al., 2009;
Liu et al., 2011; Cai and McGinnis, 2016), while nanoparticle-
based approaches for the treatment of DR have also been
investigated (Fangueiro et al., 2015). Among nanoparticles,
magnetic nanoparticles (MNPs) may represent a promising
perspective for intraocular drug delivery (Giannaccini et al.,
2017b). Indeed, intraocularly injected MNPs have been shown
to enter the retina rapidly and persistently localize within the
retinal pigment epithelium (RPE) in Xenopus and zebrafish
without inducing any tissue damage (Giannaccini et al., 2014).
Importantly, MNPs have been demonstrated to be effective
in loading and delivering molecules such as brain derived
neurotrophic factor (BDNF) and nerve growth factor (NGF)
to zebrafish eyes with an increase of their effectiveness in
preventing oxidative retinal damage (Giannaccini et al., 2018).
Here we tested the feasibility of using MNP-bound OCT
(MNP-OCT) for treatment of DR. In particular, we assessed
the efficacy of MNP-OCT in inhibiting the VEGF-induced
proangiogenic responses in HRECs, its effectiveness in protecting
ex vivo retinal explants from OS-induced apoptosis, and the
actual localization of MNP-OCT in mouse retinas in vivo after
intraocular injection. Preliminary results have been published
previously (Amato et al., 2018b).
MATERIALS AND METHODS
Nanoparticle Functionalization
Commercial MNPs were used (FluidMAG-ARA 4115, Chemicell,
Berlin, Germany). They are composed by a magnetite core of
iron oxide and an organic shell exposing carboxylic groups.
Their hydrodynamic diameter is 50 nm (product information
sheet). These MNPs are characterized by a polydispersity index
of 0.337 ± 0.022, and a negative Z potential (-38.72 ± 2.14 mV)
due to their surface functionalization with carboxylic groups
(Giannaccini et al., 2018). The nanoparticles were covalently
functionalized with OCT (Abcam, Cambridge, United Kingdom)
using an MNP/protein ratio of 3.5:1 w/w via EDC chemistry,
as previously described (Pinkernelle et al., 2015; Giannaccini
et al., 2017a,b). The functionalization procedure was conducted
entirely under sterile conditions. Briefly, MNPs were centrifuged
(18,000g) and resuspended in 4% EDC (Sigma Aldrich, St. Louis,
MO, United States) water solution. After 10 min, OCT was
added and mixed for 1 h at 4–8◦C. Finally, unbound protein was
removed by centrifugation (18,000g) and supernatant discarding.
The amount of MNP-OCT was calculated by subtraction,
measuring the protein concentration in the supernatant with the
Bradford assay. Conversely, the amount of MNPs was quantified
using the thiocyanate assay, according to a protocol published
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previously (Riggio et al., 2012). Briefly, 3 µl of MNP suspension
was resuspended in 50 µl of a solution made of 1 part of 6
M HCl and one part of 65% HNO3 (v/v) and incubated at
60◦C for 1 h. The sample was water diluted 1:10, an equal
volume of 1.5 M KSCN was added, and absorbance recorded
at 478 nm. The calibration curve was obtained with a known
amount of MNPs (y = 0.055x, R2 = 1), where y is the absorbance
at 478 nm and x is the MNP concentration (mg/ml). MNP-OCT
were stored in 20% glycerol at −20◦C. The final composition of
the MNP-OCT water solution was 1 mM OCT + 4,9 mg/mL
MNPs+ 20% glycerol.
Transmission Electron Microscopy of
MNP-OCT
The distribution, morphology and average size of MNP-OCT
were analyzed by transmission electron microscopy (TEM)
using a JEM 1010 electron microscope (Jeol, Tokyo, Japan) at
80 kV. TEM samples of MNP-OCT were prepared by placing
one drop of a diluted suspension of nanoparticles in ultrapure
water on a formvar-carbon-coated copper grid and allowing
the solvent to evaporate at room temperature. The average
particle size was evaluated by measuring the largest internal
dimension of 200 randomly chosen particles using the ruler
tool of Adobe Photoshop CS3 (Adobe Systems, Mountain View,
CA, United States).
Cell Culture
In vitro studies were performed using HRECs (ACBRI-
181, Applied Cell Biology Research Institute, Kirkland, WA,
United States). HRECs were cultured in EBM-2 (Lonza, Basel,
Switzerland) supplemented with 10% fetal bovine serum (FBS,
Sigma Aldrich) and endothelial growth factors (EGM-2MV
SingleQuot, Lonza) at 37◦C under a humidified 95%:5% (v/v)
mixture of air and CO2.
Endothelial Cell Proliferation Assay
HRECs (1 × 104) were starved with EBM-2 containing
0.5% FBS for 18 h to inactivate cell proliferation and
successively were treated with or without 40 ng/mL VEGF.
OCT bioactivity was tested by adding 1 µM OCT or
1 µM MNP-OCT in the presence or absence of VEGF.
We choose the 1 µM concentration because it has been
reported to be an effective concentration to counteract VEGF-
driven endothelial activation (Palii et al., 2008). In order
to test the nanoparticle core toxicity, an equal amount of
non-functionalized MNPs (4.9 µg/mL) were added to the
culture medium in the presence or absence of VEGF. The
dose-response analysis was performed by adding an equal
amount of OCT or MNP-OCT following a logarithmic
scalar dose correspondent to 1 µM, 0.1 µM, 0.01 µM,
or 0.001 µM. After 24 h incubation, the cell viability was
quantified spectrophotometrically using the MTT assay
(Sigma Aldrich). Absorbance was measured at 595 nm
using an iMark microplate reader (Bio-Rad Laboratories,
Hercules, CA, United States) for the proliferation rate
calculation. Analyses were performed in at least three
independent experiments. After statistical analysis, the data
from the different experiments were plotted and averaged
in the same graph.
Endothelial Cell Migration Assay
HRECs were allowed to grow to full confluence in 6-well
plates pre-coated with 0.1% gelatin and then starved with
EBM-2 containing 0.5% FBS for 18 h. The cells were then
wounded with pipette tips and washed with PBS. EBM-2
containing 0.5% FBS was added into the wells with or without
80 ng/ml VEGF and treated with OCT, MNPs or MNP-OCT
at the concentrations given above. Cell migration toward the
wounded area was evaluated after 18 h by using the ImageJ
software and an inverted phase contrast microscope (Zeiss,
Oberkochen, Germany) equipped with a 10 × objective and a
CCD camera. The percentage of the healed area was evaluated
in three independent experiments. After statistical analysis,
data from the different experiments were plotted and averaged
in the same graph.
Endothelial Cell Tube Formation Assay
The effect of OCT, MNPs, or MNP-OCT on the VEGF-
induced HREC tube formation was assessed as previously
described (Lulli et al., 2015). Briefly, 100 µl of Matrigel
Growth Factor Reduced (Corning, New York, NY, United States)
were added to a 96-well plate and allowed to solidify at
37◦C for 45 min. 1.5 × 104/well HRECs were starved with
EBM-2 containing 0.5% FBS for 18 h and then plated
onto the layer of Matrigel in 100 µL of starvation medium
with or without 80 ng/mL VEGF and treated with OCT,
MPNs or MNP-OCT at the concentrations given above.
After 6 h incubation, HREC images were acquired using an
inverted microscope equipped with a CCD camera (Zeiss).
The area occupied by tubular-like structures was measured
using the Angiogenesis Analyzer tool of ImageJ software.
Three independent experiments were performed. After statistical
analysis, data from the different experiments were plotted and
averaged in the same graph.
Animals
All the procedures were performed in compliance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research, the EU Directive (2010/63/EU), and the Italian
guidelines for animal care (DL 26/14; Permission number:
132/2019-PR). A total of 30, 4–5 week-old C57BL/6J mice
(Envigo, San Pietro al Natisone, Udine, Italy) were used in
these studies. In addition, two Balb/c mice of similar age
were used for intravitreal injections. The mice were kept in a
regulated environment (23 ± 1◦C, 50 ± 5% humidity) with
a 12 h light/dark cycle (lights on at 8:00 am) with food and
water ad libitum.
Retinal Explants
Ex vivo cultures were prepared according to published protocols
(Amato et al., 2016). Briefly, retinas were dissected, cut into
four fragments and transferred onto Millicell-CM culture inserts
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(Merck Millipore, Burlington, MA, United States) with ganglion
cells up. The retinal explants were cultured in 1 mL of
serum-free culture medium composed of 50% MEM/HEPES
(Sigma Aldrich) containing 6 mM D-glucose, 25% Hank’s buffer
salt solution (Sigma Aldrich) 25% PBS, 25 U/mL penicillin,
25 mg/mL streptomycin, 1 µg/mL amphotericin B, and 200 µM
L-glutamine. The explants were incubated for 5 days at 37◦C
under a humidified 95%/5% (v/v) mixture of air and CO2. OS
treatment consisted in adding H2O2 to a final concentration
of 100 µM. 1 µM OCT, 4.9 µg/mL MNPs, or 1 µM MNP-
OCT were added to the culture medium. The medium was
changed every other day. The dose-response experiment was
performed by adding 1 µM, 0.1 µM, 0.01 µM, or 0.001 µM
OCT or equivalent amounts of MNP-OCT to the culture
medium. Retinal explants were then incubated for 3 days without
changing the medium.
Immunofluorescence
Retinal explants were fixed in 4% paraformaldehyde in 0.1 M
PBS for 2 h and then stored in 25% sucrose in 0.1 M
PBS. Ten µm thick sections were cut with a cryostat.
Immunofluorescence was performed using a rabbit antibody
directed to active caspase-3 (1:500; Sigma Aldrich) and
appropriate secondary antibodies conjugated with Alexa Fluor
546 (Molecular Probes, Eugene, OR, United States). Retinal
layers were revealed by DAPI counterstain. Digital images were
acquired with an epifluorescence microscope (Nikon Eclipse
Ni, Nikon Europe, Amsterdam, Netherlands) using a 20x plan
apochromat objective. To perform the quantitative analysis,
four fragments, each originating from a different retina for
experimental condition, were photographed and analyzed. The
number of active caspase-3 positive cells was counted in
each fragment and normalized for the section length using
Adobe Photoshop.
Quantitative Real-Time PCR
Eight fragments per condition were pooled and total RNA
was extracted using an RNA isolation kit (RNeasy Mini Kit;
Qiagen, Hilden, Germany) and quantified. First-strand cDNA
was generated from 1 µg of total RNA using QuantiTect
Reverse Transcription Kit (Qiagen). Quantitative real-time
PCR (qPCR) was performed using SsoAdvanced Universal
SYBR Green Supermix on a CFX Connect Real-Time PCR
Detection System and software CFX manager (Bio-Rad
Laboratories). Forward and reverse primers were chosen to
hybridize to unique regions of the caspase-3 gene and of
Rpl13a, a constitutively expressed gene encoding for ribosomal
protein L13A (Mazumder et al., 2003). Primer sequences were
as follows:
Caspase-3 forward 5′-GCACTGGAATGTCATCTCGCTC
TG-3′;
Caspase-3 reverse 5′-GCCCATGAATGTCTCTCTGAGGT
TG-3’;
Rpl13a forward 5′-CACTCTGGAGGAGAAACGGAA
GG-3′;
Rpl13a reverse 5′-GCAGGCATGAGGCAAACAG
TC-3′.
Samples were compared using the relative threshold cycle
(Ct Method). The increase or decrease (x-fold) was determined
relative to a control after normalizing to Rpl13a. Three
pools of fragments per condition, each made of eight retinal
fragments originating from different retinas, were analyzed and
all reactions were run in duplicate. After statistical analysis, the
data from the different experiments were plotted and averaged
in the same graph.
Intravitreal Injections and MNP-OCT
Localization in the Retina in vivo
Both C57BL/6J and Balb/c mice were employed in the
experiments for MNP-OCT localization in the retina after
intravitreal injection. In particular, the albino Balb/c mice, in
which the RPE is not pigmented, were used to better visualize
MNP-OCT localization to the RPE in TEM preparations.
The mice were anesthetized with an intraperitoneal injection
of Avertin (1.2% tribromoethanol and 2.4% amylene hydrate
in distilled water, 0.02 mL/g body weight; Sigma Aldrich).
1 µL of 1 mM MNP-OCT was intravitreally injected using a
microsyringe (NanoFil syringe; World Precision Instruments,
Sarasota, FL, United States) equipped with a 36 gauge
needle. For MNP-OCT localization with Prussian blue staining,
C57BL/6J mice were sacrificed 8 h, 24 h or 5 days after
the injection (two mice per experimental group). The eyeballs
were enucleated, immersion fixed in 4% paraformaldehyde in
0.1 M phosphate buffer for 2 h, and then stored in 25%
sucrose in 0.1 M PBS. Subsequently, they were embedded
in cryo-gel and 10 µm thick cryostat coronal sections were
collected for staining. The RPE was de-pigmented with 0.5%
H2O2 and Prussian blue staining was used to localize the
iron oxides composing the nanoparticle core according to the
manufacturer’s protocol (Sigma Aldrich). The sections were
counterstained with pararosaniline to visualize the retinal layers.
For ultrastructural evaluation, two C57BL/6J and two Balb/c
mice were sacrificed 24 h after the intravitreal injection. Then
the eyeballs were fixed in 2,5% paraformaldehyde and 1%
glutaraldehyde and embedded in Epon 812 (Sigma-Aldrich).
Semithin sections were cut to evaluate quality and orientation
of the tissue. Ultrathin cross-sections of the eye wall were
prepared and mounted on grids, stained with UranyLess
TEM staining, and examined under a JEM 1010 electron
microscope (Jeol) at 80 kV. Images were captured using a
CCD digital camera.
Statistical Analysis
Statistical significance was evaluated with analysis of variance
(ANOVA) using the Prism 5.03 software (GraphPad Software,
San Diego, CA, United States). The experiments with a single
categorical variable (tests of toxicity and OCT bioactivity)
were analyzed using one-way ANOVA with Newman–Keuls
multiple comparison post-test. The experiments with a double-
categorical variable (OCT vs. MNP-OCT dose-response) were
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FIGURE 1 | High resolution TEM images showing aggregates of MNP-OCT in
a diluted water suspension (A). (B) Is a higher power of the right half of (A).
The inset is a higher power of the boxed area showing a small group of
MNP-OCT. The brightness and contrast of this image were modified with
Adobe Photoshop to visualize the organic coating surrounding the magnetite
core (arrowheads). (C) Shows the histogram and the fitting Gaussian curve
used to extract the average particle size. Scale bars, 200 nm in A; 100 nm in
B; 20 nm in the inset.
analyzed using two-way ANOVA followed by Bonferroni post-
test. Differences with p < 0.05 were considered significant. The
results were expressed as mean± SEM of the indicated n values.
RESULTS
TEM Analysis of MNP-OCT
As observed in TEM, MNP-OCT appeared to form aggregates
of various dimensions (Figure 1A). Single MNP-OCT
displayed variable sizes and round to oval morphology
(Figure 1B). At high magnification and with increased
image contrast, the coating composed of an organic shell
with the attached OCT around the magnetite core became
visible (Figure 1B, inset). The average size of MNP-
OCT was calculated counting 200 particles, obtaining the
histogram shown in Figure 1C. The histogram could be
fitted with a Gaussian distribution (R2 = 0.84) centered at
13.86 nm (σ = 4.09).
FIGURE 2 | Proliferation (A), migration (B), and tubulogenesis (C) of HRECs
in control (Ctrl) conditions or in the presence of VEGF (40 ng/mL for
proliferation, 80 ng/mL for migration and tubulogenesis) with or without
4,9 µg/mL MNPs, 1 µM OCT or 1 µM MNP-OCT. Values are plotted as
means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. Ctrl; §p < 0.05,
§§p < 0.01 and §§§p < 0.001 vs. VEGF; n = 3.
MNPs Do Not Affect HREC Proliferation,
Migration, and Tubulogenesis Induced by
VEGF
Untreated HRECs had a basal proliferation rate that was not
affected by the presence of MNPs in the incubation medium.
As expected, the treatment with VEGF determined an about
twofold increment of the cellular proliferation rate, and this
response did not change in the presence of MNPs (Figure 2A,
checked bars). Similar results were obtained for VEGF-induced
migration rate (Figure 2B, checked bars) and tubulogenesis
(Figure 2C, checked bars).
The Binding of OCT to MNPs Does Not
Alter OCT Effects on VEGF-Induced
HREC Proliferation, Migration, or
Tubulogenesis
The inhibitory effect of OCT on VEGF-induced HREC
proliferation, migration and tube formation has been well
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FIGURE 3 | Dose-response of the effects of OCT and of MNP-OCT on HREC
proliferation. Data are plotted as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001 vs. VEGF; §p < 0.05 vs. OCT; n = 4.
established in previous works (Palii et al., 2008). Our purpose
was to test if the covalent binding of OCT to MNP could
affect OCT bioactivity. The results showed that 1 µM OCT
or MNP-OCT reduced the VEGF-induced increase of HREC
proliferation (Figure 2A), migration (Figure 2B), and tube
formation (Figure 2C) with the same efficacy.
VEGF-Induced HREC Proliferation Is
Inhibited by MNP-OCT With Greater
Efficacy Than OCT
We performed a dose-response analysis to evaluate the efficacy
of decreasing concentrations of MNP-OCT in inhibiting VEGF-
induced HREC proliferation compared to OCT. As shown in
Figure 3, we confirmed a significant reduction of VEGF-induced
HREC proliferation in the presence of 1 µM OCT; however,
at lower concentrations, OCT effects were not significant. In
contrast, MNP-OCT were still effective at 0.1 and at 0.01 µM,
indicating a much greater efficiency than OCT in inhibiting the
VEGF effect on HREC proliferation.
The Binding of OCT to MNPs Does Not
Alter OCT Protective Effects Against
OS-Induced Apoptosis in Retinal
Explants
No differences in retinal layer thickness or general retinal
morphology were observed between untreated explants and
explants cultured in the presence of MNPs (4.9µg/mL) alone (not
shown). In contrast, active caspase-3 immunostained cells were
numerous in the inner nuclear layer (INL) and in the ganglion cell
layer (GCL) of retinal explants exposed to OS, and the number
of these cells was significantly reduced by treatment with 1 µM
OCT or MNP-OCT (Figures 4A–E). In addition, quantification
of caspase 3 mRNA in retinal explants (Figure 4F) confirmed that
the treatment with1 µM MNP-OCT had an effect similar to that
of 1µM OCT, demonstrating that OCT bioactivity in OS-exposed
retinal explants is not altered by the binding with MNPs.
OS-Induced Apoptotic Cell Death in
Retinal Explants Is Reduced by
MNP-OCT With Greater Efficacy Than
OCT
As previously reported, 1 µM OCT protects from apoptosis
retinal explants exposed to OS (Amato et al., 2016). Similar
FIGURE 4 | Representative immunofluorescence images of cleaved caspase-3 in sections of retinal explants cultured in control conditions (A), in OS (B), in OS with
1 µM OCT (C) or in OS with 1 µM MNP-OCT (D). Retinal layers are visualized with DAPI counterstain. Scale bar, 50 µm. (E) Quantitative analysis of the number of
cleaved caspase-3 immunopositive cells per unit length of retinal section. (F) Quantitative analysis of caspase-3 mRNA expression as evaluated with qPCR. Values
are indicated as mean ± SEM. ∗p < 0.05 and ∗∗p < 0.01 vs. the respective Ctrl; §p < 0.05 vs. the respective OS; n = 3 both in (E,F). GCL, ganglion cell layer; INL,
inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer.
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FIGURE 5 | (A) Representative immunofluorescence images of cleaved caspase-3 in sections of retinal explants cultured in control conditions (Ctrl), in OS and
following OCT or MNP-OCT treatment, as indicated. Retinal layers are visualized with DAPI counterstaining. Scale bar, 50 µm. (B) Quantitative analysis of the
number of cleaved caspase-3 immunopositive cells per unit length of retinal section. Values are indicated as the mean ± SEM. ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. OS;
§§§p < 0.001 vs. OCT; n = 3. Retinal layer abbreviations as in Figure 4.
to the dose-response experiment in HRECs, we performed
an experiment in OS-treated retinal explants to assess the
efficacy of decreasing concentrations of OCT and of MNP-OCT.
Significantly lower numbers of apoptotic cells were observed
after treatment with OCT down to a concentration of 0.01 µM,
while MNP-OCT were still efficient in inhibiting apoptosis at a
concentration of 0.001 µM (Figure 5).
Retinal Localization of Intravitreally
Injected MNP-OCT in vivo
The detection of MNPs using Prussian blue histological staining
8 h after the intravitreal injection revealed that MNP-OCT mostly
localized to the outer retina in close proximity to the RPE.
The density of the staining appeared asymmetrically distributed,
probably due to the position of the syringe tip in the vitreous at
the moment of the injection (Figure 6A). MNP-OCT were almost
exclusively localized to the RPE at 24 h after the injection, and
the staining appeared weaker than at 8 h and concentrated in
dense spots (Figure 6B). After 5 days from the injection, blue
spots revealing the presence of MNP-OCT were also detected
within inner retinal layers, and in particular in the INL and GCL
(Figure 6C). The ultrastructural analysis confirmed the presence
of MNP-OCT in the RPE 24 h after the injection, thereby
confirming the observations in the Prussian blue preparations.
These data also confirmed uptake of MNP-OCT by RPE cells,
since a large amount of nanoparticles was internalized in different
types of endocytic vesicles (Figures 7A,B). In addition, MNP-
OCT were also detected in the extracellular space among cells
of the INL, indicating that at this time some MNP-OCT was
still moving across the retina (Figure 7C). In particular, MNP-
OCT were observed to form dense accumulation spots probably
due to the diffusion of MNP-OCT through narrow intercellular
spaces, while several nanoparticles appeared in intimate contact
with the plasma membrane of INL cells (Figure 7D). No evidence
of MNP-OCT internalization was found in these cells, although
MNP-OCT internalization by neurons or glial cells at later times
cannot be excluded.
DISCUSSION
The use of nanoparticles as a drug delivery technology for
the treatment of ocular diseases such as DR is receiving
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increasing attention (Amato et al., 2018b; Bisht et al., 2018;
Jiang et al., 2018; Huang and Chau, 2019; Wong and Wong,
2019). The present study investigated the feasibility of using
MNPs for the delivery of the somatostatin analog OCT to
mammalian retinas. The results show that MNPs are not
toxic for retinal cells and that the conjugation of OCT
with MNPs not only does not alter, but also significantly
improves OCT bioactivity. In addition, intravitreally injected
MNP-OCT are localized to the RPE and inner retina up to
5 days post-injection.
Biocompatibility of MNP-OCT
Several reports have demonstrated that the size and the
material of the nanoparticle strongly influence nanoparticle
biocompatibility. For instance, an analysis of the toxic responses
of rat liver cells has revealed that nanoparticles of different sizes
and characterized by different core compositions differentially
affect cell viability and function demonstrating that silver
nanoparticles are highly toxic whereas aluminum, iron
oxide, manganese oxide, and tungsten nanoparticles display
little or no toxicity (Hussain et al., 2005). MNPs coated
with polyethylenoxide copolymers have been shown to be
devoid of adverse effects for the proliferation of epithelial,
endothelial, or tumor cells up to a concentration of 5 mg/mL
(Hafeli et al., 2009). Regarding the possible use of MNPs
in the eye, there are data in experimental animals showing
that MNPs are non-toxic to ocular tissues (Raju et al.,
2011). Our results show that MNPs do not affect HREC
vitality, nor their proliferation, migration or tube formation
in response to VEGF. The biocompatibility of MNPs was
further confirmed in ex vivo mouse retinal explants, where
no apoptotic activity attributable to the presence of MNPs
was observed. In addition, necrotic phenomena could be
excluded since no evidence of structural alterations of retinal
layers was recorded. Together, these data demonstrate that
MNPs, at the concentration used in our experiments, do
not cause toxic effects on either the vascular or the neural
components of the retina.
Bioactivity of MNP-OCT
The functionalization of MNPs with other molecules
consists in a series of chemical reactions leading to the
binding (either covalent or non-covalent) of the drug
to the MNP. Therefore, it is reasonable to imagine
that modifications of the drug molecular structure and
bioactivity could occur. Indeed, it has been shown that
the choice of the functionalization method is crucial
for the maintenance of the drug bioactivity (Pinkernelle
et al., 2015). For instance, the covalent binding of BDNF
or VEGF to MNPs does not affect drug bioactivity,
while NGF binding does, as demonstrated in retinas of
zebrafish larvae (Giannaccini et al., 2018). We compared
the bioactivity of MNP-OCT with that of free OCT,
showing that, after binding with MNPs, OCT maintains
its antiangiogenic potential inhibiting the VEGF-driven
activation of HRECs. Likewise, the antiapoptotic activity of
FIGURE 6 | Representative images of C57BL/6J mouse retinal sections after
8 h (A), 24 h (B), and 5 days (C) from an intravitreal injection of 1 µM
MNP-OCT. The Prussian blue staining identifies the localization of MNP-OCT
in the RPE (white arrows in B,C) and at different levels in the inner retina
(black-lined arrows in C). Pararosaniline counterstain. Scale bars, 200 µm in
(A), 30 µm in (C). Retinal layer abbreviations as in Figure 4.
OCT in OS-stressed retinal explants is preserved in MNP-
OCT. Hence, our data demonstrate that the covalent binding
of OCT to MNPs does not induce any alteration of the
drug bioactivity.
Efficacy of MNP-OCT Compared to That
of OCT
Interestingly, the comparison of the efficacy between MNP-
OCT and OCT revealed that the conjugation of OCT to MNPs
determined a significant improvement of the dose-dependent
inhibitory effect of OCT on the HREC response to VEGF
and on the OS-induced apoptosis in mouse retinal explants.
Indeed, the significant effect of MNP-OCT is maintained
at lower doses (100-fold in HRECs and 10-fold in retinal
explants) compared to free OCT, demonstrating a strong
improvement of the drug bioactivity following binding to
MNPs. Of note, the anti-apoptotic effect of MNP-OCT
in OS-treated retinal explants was still detected at the
lowest dose employed in these experiments, therefore the
possibility exists that MNP-OCT may have efficacy even
at lower concentrations than 0.001 µM. These observations
are consistent with similar results obtained in retinas of
OS-treated zebrafish larvae (Giannaccini et al., 2018). The
increased efficacy of MNP-OCT is likely to be due to the
fact that the conjugation of the drug to MNPs increases
its stability, thus improving its activity. Indeed, there are
reports in the literature showing that growth factors, such
as NGF, glia-derived neurotrophic factor, or fibroblast growth
factor-2, significantly increase their stability or undergo slower
degradation when they are conjugated to iron oxide MNPs,
suggesting that MNP binding prolongs protein half-life, thereby
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FIGURE 7 | High resolution TEM images of ultrathin retinal sections at the
level of the RPE (A,B) and of the INL (C,D). Images in (A,B) are from a Balb/c
mouse retina, in which RPE cells do not contain pigment and therefore
MNP-OCT can be easily detected. (B) is a higher power of the boxed area in
(A). In the RPE, MNP-OCT were found to be internalized in several endocytic
vesicles. The scission phase of endocytic process releasing primary endocytic
vesicle is highlighted by arrowheads (B), while other MNP-containing vesicles
are likely to represent different stages of the following intracellular trafficking
(A,B, arrows). (D) is a higher power of the boxed area in (C). The
nanoparticles in the INL were densely packed into narrow intercellular spaces
(D, black arrows) or distributed in dense spots adjacent to the extracellular
side of the plasma membrane of INL cells (D, red arrows). Scale bars, 1 µm in
(A,B,D); 2 µm in (C).
enhancing protein activity (Ziv-Polat et al., 2014; Marcus
et al., 2015). Based on these considerations, we expect that
MNP-OCT may improve OCT efficacy also in other models
of DR, more similar to the diabetic condition, as we have
observed recently that 1 µM free OCT prevents cell apoptosis
in retinal explants treated not only with OS, but also
with high glucose or with advanced glycation end-products
(Amato et al., 2016).
Intraocular Localization of MNP-OCT
Our data show that MNP-OCT preferentially localize to the
RPE following intravitreal injection in a mouse eye, similar
to previous findings in Xenopus embryos and zebrafish larvae
obtained with unconjugated MNPs or with MNPs conjugated
with neurotrophins (Giannaccini et al., 2014, 2018). In
particular, our observations are consistent with a migration
of the MNP-OCT from the vitreous chamber toward the
retina, and from the inner to the outer retina and into
the RPE, in a process that is completed within the first
24 h, although high resolution TEM images documented that
small quantities of MNP-OCT were still diffusing through
the retina at this time. Different from the findings in
Xenopus and zebrafish, we observed the presence of spots
of Prussian blue staining within inner retinal layers 5 days
after injection. This may represent a residue of the MNP
diffusion within retinal layers to reach the RPE. However,
we did not observe such pattern of Prussian blue staining
at 24 h post-injection, when all the labeling appeared to be
confined within the RPE. Therefore, we cannot exclude the
possibility that, after the first phase of migration through the
retina, the MNP-OCT diffuse back from the RPE toward the
inner retina. If this is the case, the MNPs could contribute
to the maintenance of OCT in situ and to its release over
a prolonged period of time. In this respect, it has been
reported that a single intravitreal injection of a nanoformulation
of glial cell derived neurotrophic factor was effective in
providing the sustained release of the drug in a model of
glaucoma, which resulted in protection from cell death of
retinal ganglion cells up to 11 weeks after the injection
(Checa-Casalengua et al., 2011).
At the ultrastructural level, MNP-OCT were observed inside
cells of the RPE. In particular, the RPE cells internalized
nanoparticles in endocytic vesicles such as endosomes and
no sign of cell damage was revealed, thus confirming the
MNP-OCT safety profile. MNP-OCT within the retina, in
particular at the level of the INL, were observed to form
clusters in the extracellular space, in accordance with a
model proposed previously to explain the movement of
MNPs through the retina. According to this model, MNPs
diffusing into the retinal cell layers would be forced to
move along narrow intercellular spaces, which would cause
their clusterization. Then these small MNP aggregates would
reach the RPE having a micrometric dimension ideal for
promoting engulfment by RPE cells (Kimura et al., 1994;
Giannaccini et al., 2017b). In addition, some MNP-OCT were
observed in intimate contact with the surface of some cells
in the INL. This positioning of the MNP-OCT may suggest
the presence of somatostatin receptors, which indeed are
known to be expressed by different cells types in the INL
of mammalian retinas (Thermos, 2003; Casini et al., 2005;
Cervia et al., 2008). This observation is particularly interesting
since it indicates that OCT may interact with its receptors
when still bound to MNP, therefore without necessarily being
released from MNP-OCT.
CONCLUSION
The data described here are consistent with observations in
Xenopus and zebrafish, adding the important notion that also
in mammals MNPs can constitute efficient drug carriers for
intraocular drug administration. In addition to the lack of any
toxic effect, a salient feature of MNP-mediated OCT intraocular
administration is that this procedure is likely to induce long-
term maintenance of the intraocular drug levels, thereby avoiding
the need of repeated intravitreal injections, with the consequent
drastic decrease of the risk of pathologic side effects. Further
analyses will be necessary to establish the amount of OCT
that is released in the retina and to assess the persistence of
drug effects in the long period. Nevertheless, the data presented
herein indicate that MNP-OCT may represent an efficient OCT
formulation for intraocular delivery and a promising candidate
for translation to the clinics.
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